

Date	Symposium	Symposium Title	Lecture Title	Presentation Time	Speaker	Program #
May 27 08:30-10:00	Symposium I	Targeting Cellular Adaption and Metastatic Progression	New Investigations in Ovarian Cancer Metastasis	08:30 - 09:15	Stack, Sharon	SY-01.01
			Epithelial-Mesenchymal Transition and the Progression of Ovarian Cancer	09:15 - 09:30	Vanderhyden, Barbara	SY-01.02
			Strengths and Weaknesses: Stress Adaptation in Metastatic Ovarian Cancer	09:30 - 09:45	Shepherd, Trevor	SY-01.03
			Epigenetic Therapies to Target Small Cell Carcinoma of the Ovary, Hypercalcemic Type	09:45 - 10:00	Witcher, Michael	SY-01.04
May 27 10:30-12:00	Symposium II	Immuno-oncology: From New Targets to Novel Therapies	Insights into Immune Regulation in the HGSC Tumor Microenvironment	10:30 - 11:15	Ohashi, Pamela	SY-02.01
			Therapeutic Potential of STING Agonist Based Combination Chemo-Immunotherapy in Ovarian Cancer	11:15 - 11:30	Koti, Madhuri	SY-02.02
			Expanded Ovarian Cancer Patient NK Cells Represent a Novel, Cytotoxic Phenotype and Reduce Autologous Tumour in a Patient-Derived Xenograft Ovarian Cancer Model	11:30 - 11:45	Hirte, Hal	SY-02.03
			The Evolutionary Interplay Between Lymphocytes and Cancer Cells in High-Grade Serous Ovarian Cancer	11:45 - 12:00	Zhang, Allen	SY-02.04
May 27 14:30-16:30	Symposium III	Systems Biology in Ovarian Cancer - Toward Precise Diagnostics and Treatments	How will we Achieve Precision Medicine for Women with HGSOc?	14:30 - 15:15	Brenton, James	SY-03.01
			Molecular Subtyping Roundup: How does Genomic Data help Stratify Ovarian Carcinomas?	15:15 - 15:50	Anglesio, Michael	SY-03.02
			BRCA, HRD and PARP Inhibitor Therapy for Ovarian Cancer	15:50 - 16:10	Tinker, Anna	SY-03.03
			Population-Based Genetic Testing for Ovarian Cancer Susceptibility	16:10 - 16:30	Campbell, Ian	SY-03.04
May 28 08:00-10:00	Symposium IV	Ovarian Cancer Etiology and Implications for Primary Prevention in Contemporary Populations	Introduction	08:00 - 08:05	Koushik, Anita	SY-04.01
			Germline Genetics and Ovarian Cancer Risk: implications for Prevention	08:05 - 09:00	Pharoah, Paul	SY-04.02
			Physical Activity and Ovarian Cancer Risk by Menopausal Status	09:00 - 09:30	Koushik, Anita	SY-04.03
			Vitamin D and Ovarian Cancer Risk	09:30 - 10:00	Cook, Linda	SY-04.04
May 28 10:30-12:00	Symposium V	Uncommon Ovarian and Endometrial Cancers - From Identification to Intervention	Unusual Cell of Origin + Interesting Mutation + Permissive Microenvironment = Rare Ovarian Cancer	10:30 - 11:00	Huntsman, David	SY-05.01
			Overview on Low-Grade Serous Carcinoma	11:00 - 11:15	Köbel, Martin	SY-05.02
			Improving Outcomes for Women Diagnosed with Low Grade Serous Ovarian Cancer	11:15 - 11:30	Cheasley, Dane	SY-05.03
			Strategies to Improve Outcomes in Rare Gynecologic Cancers: An Update on Low-Grade Serous Ovarian Cancer	11:30 - 12:00	Carey, Mark	SY-05.04
			Exploiting Molecular Dependencies in Ovarian Cancer to Improve Patient Outcomes	14:30 - 15:15	Stronach, Euan	SY-06.01
May 28 14:30-16:30	Symposium VI	Targeting Essential Vulnerabilities in Ovarian Cancer - From DNA Repair to Drug Resistance	Targeted and Combination Therapies: You Can RAN but You Can't Hide!	15:15 - 15:45	Mes-Masson, Anne-Marie	SY-06.02
			Chromosome Instability Increases in Drug Resistant Epithelial Ovarian Cancer (EOC): Cause or Consequence?	15:45 - 16:05	McManus, Kirk	SY-06.03
			The Anti-HIV Drug Nelfinavir is Cytotoxic Towards High-Grade Serous Ovarian Cancer Cells Regardless of Platinum Sensitivity	16:05 - 16:17	Subeha, Mahbuba	SY-06.04
			Argininosuccinate Synthase Deficient Ovarian Cancers are Sensitive to Arginine Deprivation	16:17 - 16:29	Ji, Jennifer (Xiao Ye)	SY-06.05
			Barbara Murchie Lecture	08:45-09:45	Nelson, Brad	BM-01.01
May 29 10:00-11:45	Symposium VII	Oral Session Highlighting the Next Generation of Researchers	Introduction	10:00 - 10:05	Postovit, Marie-Lynn	SY-07.01
			Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes	10:05 - 10:20	Wang, Yikan	SY-07.02
			Investigation of a Rare Germline FANCI Variant Identified in BRCA1 and BRCA2 Mutation-negative Familial Ovarian Cancer Families	10:21 - 10:36	Fierheller, Caitlin	SY-07.03
			Evaluating the Impact Diminished SKP1 and CUL1 Expression have on Chromosome Instability in High Grade Serous Ovarian Cancer	10:37 - 10:52	Lepage, Chloe	SY-07.04
			Pre-mRNA Splicing Factor 4 Kinase (PRP4K): A Novel Prognostic Biomarker in Ovarian Cancer Whose Loss is Associated With Taxane and Anoikis Resistance	10:53 - 11:08	Clarke, Livia	SY-07.05
			A Novel Signature of Mesenchymal Stromal Cells in High Grade Serous Ovarian Carcinoma	11:09 - 11:24	Hussain, Ali	SY-07.06
			Determination of Mouse Oviduct Epithelial Homeostasis and Heterogeneity to Understand the Initiation of High-Grade Serous Ovarian Cancer	11:25 - 11:40	Ford, Matthew	SY-07.07